Biogen Inc. shares remain in an uptrend despite broader market pressure from the selloff in AI-related stocks. Its "star," called Leqembi, generated $202 million in Q3 global in-market sales, up 9.8% quarter-over-quarter and 66.9% year-over-year. On November 16, Biogen said that Leqembi reduced the relative risk of progression from early to moderate/severe Alzheimer's disease by 49% versus ADNI.








